LIVE-Stream Aufzeichnung vom ASCO 2019: Brustkrebs Deutschland Round Table-Moderation: Renate Haidinger, Brustkrebs Deutschland e.V., München, mit:

LBA1008: Phase III MONALEESA7 trial of premenopausal patients withHR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results. Conclusions: RIB + ET demonstrated a clinically and statistically significant longer OS than ET alone in premenopausal pts with HR+/HER2− ABC. This is the first time that a CDK4/6 inhibitor or any targeted agent + ET has demonstrated significantly longer OS vs ET alone as initial endocrine-based therapy. Clinical trial information: NCT02278120 CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT Joseph A. Sparano, Robert James Gray, Della F. Makower, Tracy G. Lively, et al. Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx. Conclusions: Clinical risk stratification provides additional prognostic information to the 21-gene RS, but not prediction of CT benefit in the overall TAILORx population or those > 50y, and facilitates more refined estimates of absolute CT benefit for women ≤50y with a RS 16-25. (Funded by National Cancer Institute, Komen Foundation, Breast Cancer Research Foundation). Clinical trial information: NCT00310180. Powered by TCPDF (www.tcpdf.org)